Abstracts tagged "Antibodies"

Abstract Number: 2118 • 2018 ACR/ARHP Annual Meeting
Prevalence of Acquired Activated Protein C Resistance and Anti-Protein C Antibodies in Systemic Lupus Erythematosus
Giuseppe Alvise Ramirez^1,2,3,4, Hannah Cohen^5,6, David A. Isenberg^4,7 and Maria Efthymiou⁵, ¹Università Vita-Salute San Raffaele, Milan, Italy, ²Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ³Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milan, Italy, ⁴Department of Rheumatology, University College London Hospitals NHS Foundation Trust, London, United Kingdom, ⁵Haemostasis Research Unit, Department of Haematology, University College London, London, United Kingdom, ⁶Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom, ⁷University College London, London, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease characterised by increased cardiovascular risk, with a 5-20 fold increased risk for venous thromboembolism (VTE)…
Abstract Number: 2576 • 2018 ACR/ARHP Annual Meeting
Anti-Drug Antibodies, Efficacy, and Impact of Concomitant Methotrexate in Ixekizumab-Treated Patients with Psoriatic Arthritis
Christopher T. Ritchlin¹, Joseph F. Merola², Amanda M. Gellett³, Chen-Yen Lin³ and Talia Muram³, ¹University of Rochester Medical Center, Rochester, NY, ²Clinical Unit for Research Innovation & Trials, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Anti-drug antibody (ADA) development can potentially affect the efficacy of biologics; concomitant MTX decreases the development of ADA for some biologics.1 Ixekizumab (IXE), a…
Abstract Number: 168 • 2018 ACR/ARHP Annual Meeting
IgG Anti-High-Density Lipoproteins Antibodies Discriminate between Arterial and Venous Events in Thrombotic Antiphospholipid Syndrome Patients
Irene Cecchi¹, Massimo Radin², Elena Rubini³, Ana Suárez⁴, Dario Roccatello⁵, Savino Sciascia⁶ and Javier Rodríguez-Carrio⁷, ¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ²Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy., Turin, Italy, ⁴Area of Immunology, Department of Functional Biology, University of Oviedo, Oviedo, Spain, ⁵Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ⁶Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy, ⁷Bone and Mineral Research Unit, Instituto Reina Sofía de Investigación Nefrológica, REDinREN del ISCIII, Hospital Universitario Central de Asturias, Oviedo, Spain
Background/Purpose: Reliable biomarkers for risk stratification in Antiphospholipid Syndrome (APS) are still lacking. Anti-high-density lipoproteins antibodies (anti-HDL) showed promising results in predicting the development of…
Abstract Number: 2682 • 2018 ACR/ARHP Annual Meeting
Novel Antibody Against Commensal Bacterial Antigen in Prediction of the Response of Rituximab in Systemic Lupus Erythematosus
Yu-Min Kuo^1,2, Jenhao Chen³, Jean-san Chia⁴, Chiau-jing Jung⁵ and Song-Chou Hsieh⁶, ¹Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan, Taipei, Taiwan, ²Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, ³Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, National Taiwan University Hospital,Yunlin branch, Yunlin County, Taiwan, ⁴Graduate Institute of Immunology, National Taiwan University College of Medicine, Taipei, Taiwan, ⁵Department of Microbiology and Immunology, School of Medicine,, College of Medicine, Taipei Medical University, Taipei, Taiwan, ⁶National Taiwan University Hospital, Taipei, Taiwan
Background/Purpose: Streptoccocal infections can cause rheumatic fever sharing clinical presentations similar to SLE. Whether oral commensal streptococci could induce cross-reactive and pathogenic antibodies remained unknown.…
Abstract Number: 390 • 2018 ACR/ARHP Annual Meeting
Severe Axial and Pelvifemoral Muscle Damage in Immune-Mediated Necrotizing Myopathy Evaluated By Whole-Body MRI
Océane Landon-Cardinal¹, Cedi Koumako², Giulia Hardouin³, Benjamin Granger³, Harmen Reyngoudt², Jean-Marc Boisserie², Aude Rigolet¹, Baptiste Hervier¹, Nicolas Champtiaux¹, Perrine Guillaume¹, Mathieu Vautier¹, Pierre Carlier², Olivier Benveniste¹ and Yves Allenbach¹, ¹Department of Internal Medicine and Clinical Immunology and Inflammation-Immunopathology-Biotherapy Department (I2B), Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris, East Paris Neuromuscular Diseases Reference Center, Paris, France, ²Laboratoire de RMN AIM & CEA, Centre d'Explorations Fonctionnelles, Institut de Myologie, Paris, France, ³Département de Biostatistiques, Santé Publique et Information Médicale, Groupe hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France
Background/Purpose: Immune-mediated necrotizing myopathies (IMNM) are a severe condition with early muscle damage attested by MRI of thigh muscles. Presence of damage in the other…
Abstract Number: 2801 • 2018 ACR/ARHP Annual Meeting
A Novel B-Cell-Helper IL-21-Producing CD8+ T Cell Subset Involved in the Pathogenesis of Rheumatoid Arthritis
Kazuhiko Higashioka¹, Masahiro Ayano¹, Yasutaka Kimoto², Hiroki Mitoma¹, Mitsuteru Akahoshi¹, Yojiro Arinobu¹, Koichi Akashi¹, Takahiko Horiuchi³ and Hiroaki Niro⁴, ¹Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, ²Department of Internal Medicine, Kyushu University Beppu Hospital, Oita, Japan, ³Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, ⁴Department of Medical Education, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Background/Purpose: A plethora of evidence from genome-wide association studies and relevant animal models implicates a pivotal role of T cells in the pathogenesis of rheumatoid…
Abstract Number: 397 • 2018 ACR/ARHP Annual Meeting
Myositis-Specific Autoantibodies and Their Clinical Associations
Victor Tak Lung Wong¹, Ho So¹, Ricky Wai Ki Ip², Virginia W Lao³, Steve H Pang³, Lai-Shan Tam⁴, Priscilla Wong⁵, Lydia Ho Pui Tam⁶, Tsz On Lam⁷, Mei Yan Law⁸, Isaac CW Yim⁹, Tin Lok LAI¹⁰, Patrick Man Leung Lee¹¹ and Ronald Man Lung Yip¹², ¹Kwong Wah Hospital, Kowloon, Hong Kong, ²Queen Mary Hospital, Hong Kong, Hong Kong, ³Department of Medicine, Kwong Wah Hospital, Hong Kong, Hong Kong, ⁴Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, Hong Kong, ⁵Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, China, ⁶Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁷Prince of Wales Hospital, New Territories, Hong Kong, ⁸Alice Ho Miu Ling Nethersole Hospital, New Territories, Hong Kong, ⁹Department of Medicine, Tseung Kwan O Hospital, Hong Kong, Hong Kong, ¹⁰Medicine, Tseung Kwan O Hospital, Tseung Kwan O, Hong Kong, ¹¹Yan Chai Hospital, Kowloon, Hong Kong, ¹²Tung Wah Group of Hospitals, Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Myositis-specific autoantibodies (MSAs) have been shown to predict clinical features and have prognostic implications in patients with idiopathic inflammatory myopathies (IIMs), with anti-melanoma differentiation-associated…
Abstract Number: 2935 • 2018 ACR/ARHP Annual Meeting
A Practical Classification of Systemic Sclerosis Using Subset and Autoantibodies for the Purpose of Early Risk Stratification
Svetlana I. Nihtyanova¹, Emma C. Derrett-Smith², Carmen Maria Fonseca³, Voon H. Ong² and Christopher P. Denton⁴, ¹Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ²Division of Medicine, University College London, London, United Kingdom, ³Department of Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ⁴University College London, London, United Kingdom
Background/Purpose: The Le Roy et al. classification of SSc into limited and diffuse cutaneous subtype remains the most commonly used. Nevertheless, autoantibodies are much better…
Abstract Number: 700 • 2018 ACR/ARHP Annual Meeting
Immunogenicity of Originator and Biosimilar Infliximab: Anti-Drug Antibody Occurence, Cross-Reactivity and Epitope Specificities across Six Diseases. Analyses from a Norwegian Randomized Switching Trial
Guro Løvik Goll¹, Nils Bolstad², Ines Iria^3,4, Rolf Klaasen⁵, Kristin Kaasen Jørgensen⁶, Inge C Olsen⁷, Ana Valido⁸, Maria J Saavedra⁹, João E. Fonseca¹⁰, Merete Lorentzen¹¹, Cato Mork¹², Knut EA Lundin¹³, David J Warren¹⁴, Espen A. Haavardsholm¹⁵, Jorgen Jahnsen¹⁶, Tore Kvien¹⁵ and João Gonçalves¹⁷, ¹Department of Rheumathology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Medical Biochemistry,, OUS-Radiumhospitalet, Oslo, Norway, ³Dept Pharmacology, Faculdade de Farmacia da Universidade de Lisboa, Lisbon, Portugal, ⁴iMed- Research Institute for medicines, Lisbon, Portugal, ⁵Dartment of Medical Biochemistry, OUS-Radiumhospitalet, Oslo, Norway, ⁶Dept Gastroenterology, Akershus University Hospital, Lørenskog, Norway, ⁷Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁸Rheumatology, Centro Hospitalar Lisboa Norte, Lisbon, Portugal, ⁹Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria, CHLN, Lisbon, Portugal, ¹⁰Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, CHLN, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, ¹¹Dept of Dermatology, Rikshospitalet, Oslo, Norway, ¹²Dept of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway, ¹³Dept of gastroenterology, Oslo University Hospital, Oslo, Norway, ¹⁴Department of Medical Biochemistry, OUS-Radiumhospitalet, Oslo, Norway, ¹⁵Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ¹⁶Dept of Gastroenterology, Akershus University Hospital, Lørenskog, Norway, ¹⁷Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisboa, Portugal
Background/Purpose: The NOR-SWITCH study was funded by the Norwegian government to investigate switching from originator infliximab (INX) to biosimilar CT-P13, in spondyloarthritis (SpA), rheumatoid arthritis…
Abstract Number: 132 • 2017 ACR/ARHP Annual Meeting
Occupational Physical Workload and Development of Anti-Collagen Type II Antibodies in Rheumatoid Arthritis Patients
Pingling Zeng¹, Lars Alfredsson², Lars Klareskog³, Mohammed Mullazehi⁴, Saedis Saevarsdottir⁵, Camilla Bengtsson⁶ and Johan Rönnelid⁷, ¹Institute of Environmental Medicine, Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden, Stockholm, Sweden, ²The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ³Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁴Department of Immunology, Genetics and Pathology,Uppsala University, Uppsala, Sweden, Uppsala, Sweden, ⁵Karolinska Institute and Karonlinska University Hospital, Stockholm, Sweden, ⁶Inst of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁷Department of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden
Background/Purpose: We have previously observed an association between exposure to occupational physical workload (PW) and risk of developing rheumatoid arthritis (RA)[1].We posit that PW could…
Abstract Number: 521 • 2017 ACR/ARHP Annual Meeting
Update on the Clinical Phase 1 and Phase 2 Trials Investigating the Fully Human Immunocytokine Dekavil (F8IL10) in Patients with Rheumatoid Arthritis
Mauro Galeazzi¹, Gian Domenico Sebastiani², Jürgen Wollenhaupt³, Jean Dudler⁴, Christof Specker⁵, Reinhard Voll⁶, Pascal Zufferey⁷, Piercarlo Sarzi Puttini⁸, Ombretta Viapiana⁹ and Franziska Bootz¹⁰, ¹Rheumatology, University Hospital of Siena, Siena, Italy, ²Rheumatology, San Camillo Forlanini Hospital, Roma, Italy, ³Division of Reheumatology, Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ⁴Rheumatology, Cantonal Hospital Fribourg, Fribourg, Switzerland, ⁵Rheumatology, St. Josef Krankenhaus, Universitätsklinikum Essen, Esssen, Germany, ⁶Clinic for Rheumatology and Clinical Immunology, Medical Center University of Freiburg, Freiburg, Germany, ⁷Department of Rheumatology, University Hospital Lausanne, Lausanne, Switzerland, ⁸Rheumatology, Luigi Sacco Hospital, Milan, Italy, ⁹University Hospital Verona, Verona, Italy, ¹⁰Clinical Department, Philochem AG (Philogen Group), Otelfingen, Switzerland
Background/Purpose: The antibody-based targeted pharmacodelivery of cytokines by means of immunocytokines has the potential to enhance therapeutic activity at the site of disease while sparing…
Abstract Number: 944 • 2017 ACR/ARHP Annual Meeting
Long-Term Survival and Follow-up of Anti-Th/to Antibody Positive Systemic Sclerosis Patients
Devon Charlton¹, Maureen Laffoon², Thomas A. Medsger Jr.³ and Robyn T. Domsic⁴, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Rheumatology, University of Pittsburgh Medical Center, Pittsburgh, PA, ³Department of Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Anti-Th/To antibody is an autoantibody associated with systemic sclerosis (SSc), occurring in 5-10% of patients. To date, only relatively small case series have described…
Abstract Number: 1428 • 2017 ACR/ARHP Annual Meeting
Discovery and Characterization of JNJ-61178104, a Bispecific Antibody Against Human Tumor Necrosis Factor (TNF) Alpha and Interleukin (IL)-17A
Fang Shen¹, Jennifer F. Nemeth², Brian Jones¹, Ann Cai¹, Shannon Hitchcock³, Thai Dinh², Ravi Malaviya¹ and Tatiana Ort¹, ¹Immunology, Janssen R&D, Spring House, PA, ²Janssen Biotech, Janssen R&D, Spring House, PA, ³Immunology, Janssen R&D, Springhouse, PA
Background/Purpose: Tumor necrosis factor alpha (TNFa) and interleukin (IL)-17A are pleiotropic cytokines implicated in the pathogenesis of several autoimmune diseases including Rheumatoid Arthritis (RA) and…
Abstract Number: 1571 • 2017 ACR/ARHP Annual Meeting
Bimekizumab Dual Inhibition of IL-17A and IL-17F Provides Evidence of IL-17F Contribution to Chronic Inflammation in Disease-Relevant Cells
Ash Maroof¹, Remi Okoye¹, Tim Smallie¹, Dominique Baeten^2,3, Sophie Archer¹, Catherine Simpson¹, Meryn Griffiths¹ and Stevan Shaw¹, ¹UCB Pharma, Slough, United Kingdom, ²UCB Pharma, Brussels, Belgium, ³University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: IL-17A and IL-17F share structural homology and have similar biologic function.1 Although the contribution of IL-17A to immune-mediated inflammatory diseases has been widely reported,1,2…
Abstract Number: 1666 • 2017 ACR/ARHP Annual Meeting
Anti-Mitochondrial Autoantibodies in Systemic Lupus Erythematosus and Their Association with Disease Manifestations
Yann Becker¹, Renee Claude Loignon¹, Genevieve Marcoux¹, Anne-Sophie Julien², Imene Melki¹, Lihi Eder³, Eric Wagner¹, Martin Pelletier¹, Marie-Josee Hebert⁴, Clemence Belleannee¹, Joyce Rauch⁵, Melanie Dieude⁴, Paul R. Fortin⁶ and Eric Boilard¹, ¹CHU de Quebec and Universite Laval, Quebec City, QC, Canada, ²CHU de Quebec - Universite Laval, Quebec City, QC, Canada, ³Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada, ⁴CHUM and Universite de Montreal, Montreal, QC, Canada, ⁵McGill University, Montreal, QC, Canada, ⁶Medicine, CHU de Quebec - Universite de Laval, Quebec, QC, Canada
- Background/Purpose: Eukaryotic cells contain organelles called mitochondria that govern energy supply and control of cell death. Whereas damaged organs or activated cells can extrude…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].